["{\n\"step_by_step_thinking\": \"The question asks about the effect of BRAFV600E mutation on clinical response to radioiodine therapy. However, none of the provided documents mention BRAFV600E mutation. The documents discuss ret oncogene activation in papillary thyroid carcinomas, detection of metastatic thyroid carcinoma after 131-iodine administration, role of chemotherapy and radioiodine in management of thyroid cancer, and G-protein mutations in thyroid tumors. There is no information about the effect of BRAFV600E mutation on clinical response to radioiodine therapy.\",\n\"answer_choice\": \"B\"\n}"]